HALIFAX, November 1, 2018—Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the completed acquisition of Affinity Biologicals Inc., a primary manufacturer of reagents and kits used in hemostasis and thrombosis research and diagnostics. “This acquisition marks an important step in the development of our company and execution of our…

See original release here For Immediate Release HALIFAX, July 19, 2018—Precision BioLogic today unveiled data from a study using a new kit for a Modified Nijmegen-Bethesda Assay (MNBA) at the International Society on Thrombosis and Haemostasis’ Scientific and Standardization Committee (SSC) meeting in Dublin. Recognizing the need to standardize and improve Factor VIII (FVIII) inhibitor…

See original press release here Precision BioLogic Inc. Banks on Developing New Diagnostic Tools From: Atlantic Canada Opportunities Agency News release Government of Canada supports research project to advance medical technology for clinical coagulation tests May 11, 2018 – Dartmouth, NS – Atlantic Canada Opportunities Agency Helping Atlantic Canadian businesses succeed by fostering greater innovation through…

See original release New data highlights promising performance of a new kit for use in a modified Nijmegen-Bethesda Assay For Immediate Release: HALIFAX, March 13, 2018—Precision BioLogic, in collaboration with Roche and Genentech, a member of the Roche Group, unveiled data from the study of a new kit for a modified Nijmegen-Bethesda Assay (MNBA) at…

For Immediate Release HALIFAX, October 2, 2017—Precision BioLogic is pleased to recognize the tenth anniversary of the Fritsma Factor—Your Interactive Hemostasis Resource, an online educational service moderated by George Fritsma and proudly supported by Precision BioLogic. In 2006, Fritsma—a lab scientist, educator and author—began looking for a means to share knowledge, information and insight about…

Founded in 1983, Precision BioLogic (formerly Precision Biologicals) originally developed conventional diagnostic coagulation products that were sold in Atlantic Canada and some markets overseas. The company had minimal success, however, because its products had few distinct advantages over other products on the market. In 1991, with support from one of the company’s shareholders, Michael Scott,…

To see original article, click here For Immediate Release HALIFAX, Dec 1, 2016 – Tom Lynch, Chair of Precision BioLogic’s Board of Directors, is pleased to announce the appointment of Paul Empey as President and CEO of the company. Most recently Precision BioLogic’s Executive Vice President, Empey joined the organization in 2015, bringing with him…

June 13, 2016 Precision BioLogic is pleased to announce the donation of coagulation diagnostic products through the World Federation of Hemophilia (WFH) Humanitarian Aid Program. This important donation means that Precision BioLogic is the first diagnostics company to commit to supporting the WFH’s efforts to ensure that people with inherited bleeding disorders in the developing…

2015 © Copyright - Bionova